Beam

Beam Global Received Record Orders Through California and Federal Contracts from Extensions to Other Government Entities in 2022

Retrieved on: 
Wednesday, December 14, 2022
Aviation, Acquisition, Electricity, EV, General Services Administration, SAN, Beam Suntory, Government, Oi Yoi Yoi, GSA, DGS, Environment, Federal, Radioactive Isotope Beam Factory, MAS, EVS, Renewable energy, Fireworks, Beam

Beam Global’s new and expanded California DGS contract is now available to all 50 states and the federal GSA contract can also be used by a variety of non-federal government agencies.

Key Points: 
  • Beam Global’s new and expanded California DGS contract is now available to all 50 states and the federal GSA contract can also be used by a variety of non-federal government agencies.
  • Beam Global EV ARC™ off-grid EV charging systems qualify as disaster preparedness assets because they continue to charge EVs during grid outages and can be equipped with an emergency power panel.
  • Purchases through these two contract vehicle extensions of Beam products were a record $6.6 million in 2022 to date, an increase YOY of over 4000%.
  • Except to the extent required by law, Beam Global expressly disclaims any obligation to update any forward-looking statements.

Beam Therapeutics Presents First In Vivo Proof of Concept Preclinical Data on Multiplex Base Edited ESCAPE Platform for Non-Genotoxic Conditioning Regimen for Patients with Sickle Cell Disease Ahead of Autologous Transplant

Retrieved on: 
Saturday, December 10, 2022
Cell, Annual report, Degenerative disease, Security (finance), Antibody, Safety, DNA, Fetal hemoglobin, Stem cell, Biotechnology, Gene editing, CD34, SCD, Mab, Toxicity, ESCAPE, Sickle cell disease, Patent, COVID-19, Patient, Failure, Pharmaceutical industry, Vaccine, Health, Beam, CD117

Beam is advancing ESCAPE as part of its long-term strategy to support broad accessibility of base editing treatments for patients with sickle cell disease (SCD) and other hematologic diseases.

Key Points: 
  • Beam is advancing ESCAPE as part of its long-term strategy to support broad accessibility of base editing treatments for patients with sickle cell disease (SCD) and other hematologic diseases.
  • The base edit to CD117, a well-categorized conditioning target, results in amino acid substitutions and is intended to allow these HSCs to evade elimination by the conditioning antibody.
  • During the poster session, Beam will also present additional in vivo data on ESCAPE-2, supporting its continued advancement and evaluation.
  • Beam Therapeutics (Nasdaq: BEAM) is a biotechnology company committed to establishing the leading, fully integrated platform for precision genetic medicines.

Beam Global Shipped and Deployed Record Number of EV ARC™ Sustainable EV Charging Systems in November 2022

Retrieved on: 
Wednesday, December 7, 2022
Aviation, Acquisition, Electricity, EV, SAN, Beam Suntory, Beam, ARC, Environment, Radioactive Isotope Beam Factory, EVS, Growth, Renewable energy

SAN DIEGO, Dec. 07, 2022 (GLOBE NEWSWIRE) -- Beam Global , (Nasdaq: BEEM , BEEMW), the leading provider of innovative sustainable products and technologies for electric vehicle (EV) charging, energy storage, energy security and outdoor media, announced that it shipped and deployed a record number of sustainable EV ARC™ EV charging systems in the month of November, higher than any other month in company history.

Key Points: 
  • SAN DIEGO, Dec. 07, 2022 (GLOBE NEWSWIRE) -- Beam Global , (Nasdaq: BEEM , BEEMW), the leading provider of innovative sustainable products and technologies for electric vehicle (EV) charging, energy storage, energy security and outdoor media, announced that it shipped and deployed a record number of sustainable EV ARC™ EV charging systems in the month of November, higher than any other month in company history.
  • Beam Global is a clean technology leader providing innovative, sustainable products and technologies for electric vehicle (EV) charging, energy storage, energy security and outdoor media.
  • Core platforms include Beam EV ARC™ and Solar Tree® sustainable EV charging systems, Beam AllCell™ high-performance energy storage solutions, energy resiliency and disaster preparedness products and a deep patent library.
  • Beam EV ARC™ EV charging infrastructure systems support any quality brand EV charging service equipment, and Beam AllCell™ battery solutions power micro-mobility, terrestrial EVs, aviation, maritime and recreational vehicles as well as stationery and energy-security platforms.

Beam Therapeutics Named to Boston Globe’s Top Places to Work List for 2022

Retrieved on: 
Friday, December 2, 2022
Policy, Biotechnology, Health, Boston, Beam, DNA, Patient, Culture, Gene editing, Boston Business Journal, Pharmaceutical industry, Management, Health insurance

4 on the Boston Globes 2022 Top Places to Work in the Large Companies category, marking its fourth consecutive year as an honoree.

Key Points: 
  • 4 on the Boston Globes 2022 Top Places to Work in the Large Companies category, marking its fourth consecutive year as an honoree.
  • The Boston Globes Top Places to Work , which will be featured in the print edition of Sundays paper, recognizes the most admired workplaces in the state, voted on by the people who know them best their employees.
  • In addition to its recognition as one of the Top Places to Work, Beam was named to the 2022 Best Places to Work list by the Boston Business Journal.
  • Beam Therapeutics (Nasdaq: BEAM) is a biotechnology company committed to establishing the leading, fully integrated platform for precision genetic medicines.

Beam Therapeutics Announces FDA Has Lifted the Clinical Hold on the Investigational New Drug Application for BEAM-201

Retrieved on: 
Friday, December 2, 2022
Biotechnology, Medicine, Investigational New Drug, COVID-19, Cell engineering, Annual report, FDA, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, DNA, Gene editing, Patient, Disease, Security (finance), Patent, Food, Pharmaceutical industry, IND, Beam

BEAM-201 is a potent and specific anti-CD7, multiplex-edited, allogeneic chimeric antigen receptor T-cell development candidate.

Key Points: 
  • BEAM-201 is a potent and specific anti-CD7, multiplex-edited, allogeneic chimeric antigen receptor T-cell development candidate.
  • We believe the future of cell therapy involves high levels of cell engineering, enabled by multiplex base editing technology.
  • Beam Therapeutics (Nasdaq: BEAM) is a biotechnology company committed to establishing the leading, fully integrated platform for precision genetic medicines.
  • This press release contains hyperlinks to information that is not deemed to be incorporated by reference in this press release.

FX Presents Kindred: A Gallery Through Time

Retrieved on: 
Wednesday, November 30, 2022
Human, Black Woman, Magic, CISE, American Express, FX, Blood, Life, Vogue (magazine), Television, Black, Protozoa Pictures, Plant, Harold, Family, Research, Kindred, Hugo, Weeping Angel, Garlic, Salmon, Los Angeles Times, South Coast Botanic Garden, FX (TV channel), Sunset (magazine), Beam, Post

LOS ANGELES, Nov. 30, 2022 /PRNewswire/ -- FX is proud to announce Kindred: A Gallery Through Time - a two-day, multimedia gallery show inspired by the new original series FX's Kindred. The free installation will be held at Band of Vices (5351 W Adams Blvd, Los Angeles, CA 90016) and open to the public from 12pm - 4pm on Thursday December 8th and 10am-5pm on Friday December 9th. FX's Kindred premieres Tuesday December 13th with all eight episodes streaming on Hulu.

Key Points: 
  • But, before she can settle into her new home, she finds herself being violently pulled back and forth in time.
  • She emerges at a nineteenth-century plantation, a place remarkably and intimately linked with Dana and her family.
  • Showcasing the restaurant group's ethos of embracing locally sourced ingredients, Post & Beam utilizes local farms to create a Southern-inspired menu.
  • Queen has been covered in the LA Times, Vogue Magazine, Sunset Magazine and a spot on Beyonc's Black Parade Route.

Beam Therapeutics to Participate in the BofA Securities 2022 Virtual Biotech SMID Cap Conference

Retrieved on: 
Wednesday, November 30, 2022
DNA, Gene editing, Biotechnology, Patient, Bank of America, Conference, Beam, Fine chemical

CAMBRIDGE, Mass., Nov. 30, 2022 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that management will participate in a fireside chat during the BofA Securities 2022 Virtual Biotech SMID Cap Conference on Wednesday, December 7, 2022 at 2:55 p.m.

Key Points: 
  • CAMBRIDGE, Mass., Nov. 30, 2022 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that management will participate in a fireside chat during the BofA Securities 2022 Virtual Biotech SMID Cap Conference on Wednesday, December 7, 2022 at 2:55 p.m.
  • Beam Therapeutics (Nasdaq: BEAM) is a biotechnology company committed to establishing the leading, fully integrated platform for precision genetic medicines.
  • This has the potential to enable a wide range of potential therapeutic editing strategies that Beam is using to advance a diversified portfolio of base editing programs.
  • Beam is a values-driven organization committed to its people, cutting-edge science, and a vision of providing life-long cures to patients suffering from serious diseases.

Beam Global Receives Multi-Unit Reorder from City of San Diego

Retrieved on: 
Tuesday, November 29, 2022
EVS, Environment, SAN, Enel, City, Face, Government, EV, Electricity, Pro Evolution Soccer, Transportation in Oslo, Aviation, ARC, Beam Suntory, Acquisition, Beam, Fireworks

"After a year of thoroughly testing EV ARC systems, the City of San Diego has given the thumbs up for further orders, joining many other municipalities who are increasing their fleets of Beam Global products like the recent $5.3M reorder from New York City.

Key Points: 
  • "After a year of thoroughly testing EV ARC systems, the City of San Diego has given the thumbs up for further orders, joining many other municipalities who are increasing their fleets of Beam Global products like the recent $5.3M reorder from New York City.
  • EV ARC systems are rapidly deployed without digging up city streets and parking areas, without expensive upgrades to city electrical circuitry, and without concern for high utility costs, saving taxpayers money, said Beam Global CEO Desmond Wheatley.
  • Based in San Diego and Chicago, the company produces Made-in-America products with the mission to Lead the World to Clean Mobility.
  • Except to the extent required by law, Beam Global expressly disclaims any obligation to update any forward-looking statements.

Beam Global Receives $11.7M Order for the U.S. Department of Veterans Affairs for 140 EV ARC™ Systems*

Retrieved on: 
Thursday, November 17, 2022
SAN, Transport, EV, U.S. Department of Veterans Affairs, Office of Inspector General, U.S. Department of Defense Strategy for Operating in Cyberspace, Beam Suntory, Environment, Inflation, Disaster, State, Growth, General Services Administration, State government, Government, Electricity, NYSE, Aviation, MAS, Acquisition, EVS, ZEVS, Veterans' affairs, GSA, Executive order, Beam, Renewable energy, Veteran

GSA is partnering with Veterans Affairs to build a more sustainable future for its fleet and its facilities across the country.

Key Points: 
  • GSA is partnering with Veterans Affairs to build a more sustainable future for its fleet and its facilities across the country.
  • VAs EV ARC systems support Executive Order 14057 calling for 100% zero-emission federal fleet light duty vehicle acquisitions by 2027 and will support VAs growing fleet of ZEVs that help serve Veterans.
  • We are thrilled to see American-made EV ARC systems going to the first of the 1,255 medical and administrative Veterans Affairs locations across the U.S. We proudly employ veterans and invite more to join us, said Beam Global CEO Desmond Wheatley.
  • Core platforms include Beam EV ARC and Solar Tree sustainable EV charging systems, Beam AllCell high-performance energy storage solutions, energy resiliency and disaster preparedness products and a deep patent library.

Beam Global Receives $29.4M Order from TechFlow to Provide 367 EV ARC™ Systems to the U.S. Army*

Retrieved on: 
Wednesday, November 16, 2022
EVS, Environment, SAN, United States Army Installation Management Command, IMCOM, Enel, Executive, White House, Army of the United States, ZEVS, Military personnel, Government, EV, Disaster, State, Electricity, Army, Aviation, Executive order, Federation, Beam Suntory, Acquisition, Beam, Renewable energy

We evaluated the requirements of the U.S. Army and determined that the Beam Global EV ARC systems offered the best solution to meet the Armys challenging off-grid EV charging requirements, said TechFlow COO Mark Carter.

Key Points: 
  • We evaluated the requirements of the U.S. Army and determined that the Beam Global EV ARC systems offered the best solution to meet the Armys challenging off-grid EV charging requirements, said TechFlow COO Mark Carter.
  • Off-grid and powered by renewable energy, the EV ARC systems are rapidly deployed turnkey sustainable charging systems requiring no construction, no electrical work and no utility connection.
  • The EV ARC systems can be connected to the grid in the event that the Army choses to do so.
  • Beam Globals Made-in-America EV ARC systems are the only 100% solar-powered, transportable, rapidly deployed EV charging systems that fit in a single parking space without reducing available parking.